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PEE3
COSTS AND CONSEQUENCES OF 
OLOPATADINE 0.1% VERSUS CROMOLYN 
SODIUM 2% IN THE TREATMENT OF SEASONAL 
ALLERGIC CONJUNCTIVITIS
Lafuma A1, Fagnani F1, Nuijten M2, Berdeaux G3
1Cemka, Bourg-La-Reine, France; 2Medtap International, Jisp, 
Netherlands; 3Alcon, Rueil-Malmaison, France
OBJECTIVE: The aim of this study was to compare the
costs and clinical consequences of olopatadine, a new
topical chemical entity with a dual mechanism of action
(anti-histamine and mast cell stabilizer) to those of topi-
cal cromolyn sodium (CS) in the treatment of seasonal al-
lergic conjunctivitis in Belgium, France, Germany, Neth-
erlands, Norway, Portugal and Sweden.
METHODS: A randomized, controlled, double-blind,
multi-country clinical trial compared the efficacy and
safety of olopatidine 0.1% bid and cromolyn sodium 2%
qid. An economic comparison of first line and first-line
failure treatments with olopatadine versus CS was mod-
eled using clinical trial results and a standard cost ap-
proach. A societal perspective was adopted. Cost of fail-
ure was established from Pinto (2001).
RESULTS: A total of 185 patients (91 olopatadine, 94
CS) presenting with SAC were treated over 42 days. At
day 42, olopatadine-treated patients had lower itching
(P  0.05) and redness (P  0.05) scores. The first-line,
treatment-failure rate was 12.5% less (P  0.02) in olo-
patadine-treated patients. Olopatadine patients had a 1.6
greater chance (P  .0001) of having a day without
symptoms, from day 1 to day 42. Olopatadine was as
safe as CS and well tolerated. According to Pinto, cost of
failure varied across countries from €48 to €72. Savings
per episode due to avoiding failures with olopatadine
were €7.00 in Belgium, €8.68 in France, €8.66 in Ger-
many, €6.12 in NL, €6.02 in Norway, €8.43 in Por-
tugal and €8.96 in Sweden. Sensitivity analyses were
conducted which confirmed the robustness of our find-
ings.
CONCLUSION: Based on results of a randomized clini-
cal trial, and resources and costs associated with failure
estimated from the literature, our model found that olo-
patadine is a cost-saving alternative to CS and offers
more clinical benefits to patients. Results were consistent
over all study countries.
PEE4
WELFARE COSTS OF VISUAL IMPAIRMENT
Remak E1, Chambers M1, Kennedy-Martin T2
1Medtap International, London, UK; 2Lilly, Surrey, UK
OBJECTIVE: The burden of sight impairment on govern-
ments’ welfare care budgets is large, and generally greater
than the associated health-care costs. The objective of
this study was to summarise and quantify the range of
welfare and social care benefits available to individuals
with sight impairment in nine countries.
METHODS: Local language literature searches, interviews
with representatives of benefit agencies, patient organisa-
tions, and clinical experts using a standard set of questions
adapted to local circumstances. ‘Typical’ cases were defined
according to age, family support and level of impairment.
RESULTS: Clinical criteria (e.g. visual acuity), functional
state or both may determine eligibility for benefits. Basic
monthly disability benefits reported, ranged from $159
(UK) to $479 (Germany). Countries with lower values
(UK, Sweden) provide a wider range of services free at
the point of use or higher benefits related to income or in-
ability to work. Higher levels of benefits in other coun-
tries are intended to cover direct purchase of services.
Benefits covering inability to work range from $135
(Spain) to $793 (Sweden), and for caring responsibilities
from $226 (UK) to $773 (France) per month. In most
countries the range of services/benefits for ‘typical’ cases
could be assessed.
CONCLUSION: Multinational studies assessing the eco-
nomic impact of sight impairment face problems due to
the fragmentation of payments and services across organ-
isations within each country, different financing struc-
tures and systems of payment/service organisations in dif-
ferent countries, and a lack of centrally held information
about numbers of claims in relation to the underlying
condition. It is necessary to tailor prospective studies to
the welfare systems in each country in order to capture
such costs and to ensure relevance of economic argu-
ments to the local environment. Decision-makers should
be encouraged the use of a wider economic perspective
when considering interventions preventing or delaying
the progress of visual impairment.
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Alio y Sanz J1, Martinez J2, Magaz S3, Badia X3, Berdeaux G4
1Insituto Oftalmologico de Alicante, Alicante, Spain; 2Instituto 
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OBJECTIVE: To compare the costs and consequences of
three strategies for correction of mild to moderate myo-
pia: laser in situ keratomileusis (Lasik), glasses and con-
tact lenses (CL).
METHODS: A Markov model compared the present value
of Lasik, glasses and CL. A structured questionnaire was
administered to 40 patients to collect resource utilization
data including direct medical and indirect non-medical
costs (transportation, time spent, hotel, spectacles, CL,
Lasik, cleaning stuff, visits to ophthalmologist, optome-
trist, optic centre, and adverse events linked to Lasik and
CL). Time horizon varied from 10 to 30 years with a 5%
discount rate. The economic perspective was that of the
Spanish society. Full sensitivity analyses were conducted.
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RESULTS: Depending on the time horizon, Lasik saved
from 18 to 278 km of distance to care centres against
spectacles and from 405 to 1,436 km against CL. Time
spent to care for visual acuity was found similar between
Lasik and CL but up to 1180 additional hours were spent
by CL wearers. Lasik saved from 4.69 to 12.07 spectacles
and from 28 to 84 cleaning packs, 18 to 50 visits to the
optic centre in comparison to glasses and 41 to 117 visits
when compared to CL. Lasik saved 4.7 to 12.2 visits for
correcting VA versus glasses or CL. Lasik avoided 95 to
295 per 10,000 cases of CL-related keratitis. CL were al-
ways more costly than Lasik which was always more
costly than glasses. The difference between glasses and
Lasik were from €1,595 to €2,521, and savings were
from €2,277 to €7,905 in comparison to CL.
CONCLUSION: Our study found that the Lasik strategy
was cost saving in comparison to CL strategy and more
expensive than the glasses strategy, without accounting
for potential non-monetary benefits of Lasik over glasses.
PEE6
PROSTAMIDES VS. COMBINATION PRODUCTS 
FOR GLAUCOMA TREATMENT: EFFECTIVENESS 
AND COST CONSIDERATIONS
Evans S1, Doyle J1, Casciano J1, Steeds C2, Walt J3
1The Analytica Group, New York, NY, USA; 2Allergan Ltd, 
Buckinghamshire, UK; 3Allergan Inc, Irvine, CA, USA
OBJECTIVE: Prostamides have recently been introduced
for the treatment of glaucoma patients. We wanted to un-
derstand and evaluate the effectiveness and cost of new
anti-glaucoma medications and study the potential cost-
savings role that newer therapies may play in the preven-
tion of glaucoma progression to blindness. In this study,
estimated effectiveness and costs of a prostamide and a
representative from another fairly new category of anti-
glaucoma medications, the combination products, were
compared from a payer perspective.
METHODS: A pharmacoeconomic model was con-
structed based on a three-month randomized controlled
efficacy trial comparing Lumigan (bimatoprost 0.03%, a
new synthetic prostamide) and Cosopt (a fixed combina-
tion product of timolol 0.5% and dorzolamide 2.0%).
The clinical trial evaluated the percent of patients achiev-
ing various target intraocular pressures (IOPs) through-
out the day, and the cost of treatment to achieve target
calculation was based on the estimated effectiveness
from the trial. Total expected annual treatment costs in-
cluded direct costs of both medications and ophthalmol-
ogy visits.
RESULTS: With bimatoprost, 30% of patients (N  27)
reached and maintained a target IOP  17 mm Hg for all
measurements throughout the day vs. 17% with the com-
bination product (N  15; p  .05). Average expected
annual treatment costs, incorporating the costs of treat-
ment success and failure (requiring additional medica-
tions and office visits) were €485 vs. €471 for bimato-
prost vs. the combination product, respectively. Cost-
effectiveness, calculated as medication cost/expected ef-
fectiveness, based on patients achieving a target IOP at
three months of  17 mm Hg, was €139 vs. €190 for bi-
matoprost vs. the combination product, respectively.
CONCLUSION: Annual expected treatment costs for
prostamides and combination products are similar. How-
ever, when cost-effectiveness is considered, due to a greater
percentage of glaucoma patients achieving ideal target
treatment goals with prostamides, prostamides appear to
be more cost-effective than combination products.
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THE BURDEN OF AGE-RELATED MACULAR 
DEGENERATION––RESULTS OF A COHORT 
STUDY IN TWO FRENCH REFERRAL 
CARE CENTERS
Bonastre J1, Le Pen C2, Soubrane G3, Quentel G4
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OBJECTIVE: The objective was to describe the socio-
economic impact of age-related macular degeneration
(AMD) and to assess, on a yearly basis, its medical and
social costs.
METHODS: A multicenter observational study was car-
ried out in a sample of 105 patients. Two ophthalmic re-
ferral care centers participated in the study. All subse-
quent patients who consulted during a three-week period
were included provided they presented the following cri-
teria:  60 years of age; an exudative form of AMD with
a distance visual acuity in the best eye  0.5. Data col-
lected included clinical items, treatment, medical follow-
up and transportation costs. The impact of AMD on the
living conditions and welfare payments related to visual
impairment were also recorded. A payer perspective was
used. Age and severity of disease were examined as cost
factors.
RESULTS: Mean age was 79.3 years and ranged from
62.8 to 95. Median distance visual acuity in the best eye
was 0.16 and average length of evolution was 3.5 years.
Over a three-month period, patients had an average of
2.6 visits to the ophthalmologist. Thirty percent of the
patients received vascular medications and 72.4% had re-
ceived previous photocoagulation treatment. Only 10 %
had benefited from visual rehabilitation. Hospitalizations
were rare (3%). AMD annual cost per patient was
€3,872.99 [3,163.19; 4,582.80]. Fifty percent of this was
attributed to medical costs. Other major cost components
were home help at €904.94 [485.40; 1,324.33] and
transportation costs for care at €542.72 [154.28;
931.16]. Total cost increased with age and with the loss
of visual acuity.
CONCLUSION: This study assesses the cost of resources
consumed, and probably underestimates the burden of
AMD. Indeed, the need for assistance in every day life is
important. Related costs being supported by the patient,
the recourse to expensive aids is very limited.
